



**PATENT**

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**James Hendrix et al**

Examiner:

Art Unit: 1614

Application No.: 10/078,225

Filed: 19 February 2002

Title: **NOVEL HETEROCYCLIC  
SUBSTITUTED CARBONYL  
DERIVATIVES AND THEIR USE AS  
DOPAMINE D3 RECEPTOR LIGANDS**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Commissioner  
for Patents, Washington, D.C. 20231, on

Date of Deposit

Signature

**LATE SUBMISSION OF DECLARATION**  
**UNDER 37 C.F.R. 1.53(f)**


Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING  
DATE GRANTED" which was mailed on 8 May, 2002 and which indicated that the oath or  
declaration was missing, Applicants submit herewith the Declaration for the present application and  
a copy of Form PTO-1533.


Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner  
is hereby authorized to charge any additional fees which may be required by this paper, or credit any  
overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

  
Barbara E. Kury, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Docket No. A 4015 US NP




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/078,225	02/19/2002	James A. Hendrix	A4015 US NP

005487  
AVENTIS PHARMACEUTICALS, INC.  
PATENTS DEPARTMENT  
ROUTE 202-206, P.O. BOX 6800  
BRIDGEWATER, NJ 08807-0800



CONFIRMATION NO. 6185

FORMALITIES LETTER



\*OC000000008059798\*

Date Mailed: 05/08/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

**Items Required To Avoid Abandonment:**

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

**Items Required To Avoid Processing Delays:**

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

**SUMMARY OF FEES DUE:**

Total additional fee(s) required for this application is \$130 for a Large Entity

- \$130 Late oath or declaration Surcharge.

*A copy of this notice **MUST** be returned with the reply.*

*Meserth*

11/07/2002 RHEBROHT 00000053 181982 10078225  
01 FC:1051 130.00 CH

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

**BEST AVAILABLE COPY**



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/078,225	02/19/2002	1614	2298	A 4015 US NP		90	5

CONFIRMATION NO. 6185

005487

ROSS J. CEHLER  
AVENTIS PHARMACEUTICALS INC.  
ROUTE 202-206, MAIL CODE: D-303A  
BRIDGEWATER, PA 08807

UPDATED FILING RECEIPT



\*OC000000009151556\*

*Wrong State  
Address. Paper Reprinted and Mailed out.*

Date Mailed: 11/25/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

James A. Hendrix, Hillsborough, NJ;  
Horst Hemmerle, Indianapolis, IN;  
Matthias Urmann, Eschborn, GERMANY;  
Gregory M. Shutske, Pittstown, NJ;  
Joseph T. Strupczewski, Flemington, NJ;  
Kenneth J. Bordeau, Kintnersville, PA;  
John G. Jurcak, Bethlehem, PA;  
Thaddeus R. Nieduzak, Bridgewater, NJ;  
Sharon A. Jackson, Whitehouse Station, NJ;  
Paul Angell, Liberty Township, OH;  
James P. Carey, Cincinnati, OH;  
George Lee, Somerville, NJ;  
David Fink, Lebanon, NJ;  
Jean-Francois Sabuco, Paris, FRANCE;  
Yulin Chiang, Convent Station, NJ;  
Nicola Collar, Madison, NJ;

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/269,672 02/16/2001

**Foreign Applications**

UNITED KINGDOM 0117577.7 07/19/2001

If Required, Foreign Filing License Granted: 05/08/2002

Projected Publication Date: 03/06/2003

**BEST AVAILABLE COPY**

Non-Publication Request: No

Early Publication Request: No

**Title**

Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).